Literature DB >> 20880011

Power and sample size estimation for the clustered wilcoxon test.

Bernard Rosner1, Robert J Glynn.   

Abstract

The Wilcoxon rank sum test is widely used for two-group comparisons of nonnormal data. An assumption of this test is independence of sampling units both within and between groups, which will be violated in the clustered data setting such as in ophthalmological clinical trials, where the unit of randomization is the subject, but the unit of analysis is the individual eye. For this purpose, we have proposed the clustered Wilcoxon test to account for clustering among multiple subunits within the same cluster (Rosner, Glynn, and Lee, 2003, Biometrics 59, 1089-1098; 2006, Biometrics 62, 1251-1259). However, power estimation is needed to plan studies that use this analytic approach. We have recently published methods for estimating power and sample size for the ordinary Wilcoxon rank sum test (Rosner and Glynn, 2009, Biometrics 65, 188-197). In this article we present extensions of this approach to estimate power for the clustered Wilcoxon test. Simulation studies show a good agreement between estimated and empirical power. These methods are illustrated with examples from randomized trials in ophthalmology. Enhanced power is achieved with use of the subunit as the unit of analysis instead of the cluster using the ordinary Wilcoxon rank sum test.
© 2010, The International Biometric Society.

Entities:  

Mesh:

Year:  2010        PMID: 20880011      PMCID: PMC3119759          DOI: 10.1111/j.1541-0420.2010.01488.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  7 in total

1.  Extension of the rank sum test for clustered data: two-group comparisons with group membership defined at the subunit level.

Authors:  Bernard Rosner; Robert J Glynn; Mei-Ling T Lee
Journal:  Biometrics       Date:  2006-12       Impact factor: 2.571

2.  Power and sample size estimation for the Wilcoxon rank sum test with application to comparisons of C statistics from alternative prediction models.

Authors:  B Rosner; R J Glynn
Journal:  Biometrics       Date:  2008-05-28       Impact factor: 2.571

3.  A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1990-09

4.  Incorporation of clustering effects for the Wilcoxon rank sum test: a large-sample approach.

Authors:  Bernard Rosner; Robert J Glynn; Mei-Ling Ting Lee
Journal:  Biometrics       Date:  2003-12       Impact factor: 2.571

5.  Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment.

Authors:  Eliot L Berson; Bernard Rosner; Michael A Sandberg; Carol Weigel-DiFranco; Ann Moser; Robert J Brockhurst; K C Hayes; Chris A Johnson; Ellen J Anderson; Alexander R Gaudio; Walter C Willett; Ernst J Schaefer
Journal:  Arch Ophthalmol       Date:  2004-09

6.  Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses.

Authors:  Eliot L Berson; Bernard Rosner; Michael A Sandberg; Carol Weigel-DiFranco; Ann Moser; Robert J Brockhurst; K C Hayes; Chris A Johnson; Ellen J Anderson; Alexander R Gaudio; Walter C Willett; Ernst J Schaefer
Journal:  Arch Ophthalmol       Date:  2004-09

7.  A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa.

Authors:  E L Berson; B Rosner; M A Sandberg; K C Hayes; B W Nicholson; C Weigel-DiFranco; W Willett
Journal:  Arch Ophthalmol       Date:  1993-06
  7 in total
  8 in total

1.  Power and sample size calculations for the Wilcoxon-Mann-Whitney test in the presence of death-censored observations.

Authors:  Roland A Matsouaka; Rebecca A Betensky
Journal:  Stat Med       Date:  2014-11-13       Impact factor: 2.373

2.  Optimal design of longitudinal data analysis using generalized estimating equation models.

Authors:  Jingxia Liu; Graham A Colditz
Journal:  Biom J       Date:  2016-11-23       Impact factor: 2.207

3.  Relative efficiency of equal versus unequal cluster sizes in cluster randomized trials with a small number of clusters.

Authors:  Jingxia Liu; Chengjie Xiong; Lei Liu; Guoqiao Wang; Luo Jingqin; Feng Gao; Ling Chen; Yan Li
Journal:  J Biopharm Stat       Date:  2020-09-24       Impact factor: 1.051

4.  Methods for sample size determination in cluster randomized trials.

Authors:  Clare Rutterford; Andrew Copas; Sandra Eldridge
Journal:  Int J Epidemiol       Date:  2015-07-13       Impact factor: 7.196

5.  Personalized analysis of pathway aberrance induced by sevoflurane and propofol.

Authors:  Xianqiang Zheng; Jing Cong; Huidong Zhang; Xueliang Chu
Journal:  Mol Med Rep       Date:  2017-08-21       Impact factor: 2.952

6.  Promoting school lunch fruit and vegetable intake through role modeling: a pilot study.

Authors:  Stephanie S Machado; Michael Burton; Wes Loy; Kyle A Chapman
Journal:  AIMS Public Health       Date:  2020-01-07

7.  Bevacizumab's Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC.

Authors:  John M Varlotto; Yating Wang; Zhuoxin Sun; Heather A Wakelee; Suresh Ramalingam; Joan Schiller
Journal:  JTO Clin Res Rep       Date:  2022-01-10

8.  The effectiveness of far-infrared irradiation on foot skin surface temperature and heart rate variability in healthy adults over 50 years of age: A randomized study.

Authors:  Tai-Chu Peng; Su-Ping Chang; Lee-Mei Chi; Li-Mei Lin
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.